title: Quinazolinone cholecystokinin (CCK)-B antagonists decrease midbrain dopamine unit activity.
authors.affiliation: Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, Indiana 46285.
authors.forename: K
authors.initials: K
authors.lastname: Rasmussen
authors.forename: M J
authors.initials: MJ
authors.lastname: Yu
authors.forename: J F
authors.initials: JF
authors.lastname: Czachura
mesh_terms: D000818:Animals; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D004594:Electrophysiology; D007211:Indoles / Q000494:pharmacology; D008297:Male; D008636:Mesencephalon / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D011799:Quinazolines / Q000494:pharmacology; D052999:Quinazolinones; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D007211:Indoles; D011799:Quinazolines; D052999:Quinazolinones; C090814:LY 247348; C090815:LY 202769; D002766:Cholecystokinin